Summary
Telomerase is an RNA-dependent polymerase that synthesizes telomeric DNA (TTAGGG)n repeats. The overall goal of our work was to establish human cancer models that can be used to design clinical trials with telomerase inhibitors. The objectives of this study were (1) to set up a human breast cancer system that allows evaluation of the effects of telomerase inhibitors in cultured cells using a non-amplified telomerase assay and (2) to test this system using two drugs (cisplatin and TMPyP4) that affect the telomerase expression in breast cancer cells in culture. We first compared the telomerase activity in a variety of human breast cancer cell lines to that of other tumour types using a new biotinylated-primer extension assay. Our method, based on a non-amplified primer extension assay shows the direct incorporation of 32P-labelled nucleotides induced by telomerase on human telomeric primers. The 32P-dGTP labelled telomerase-extended 5′-biotinylated (TTAGGG)3 primer can subsequently be separated using streptavidin-coated magnetic beads. As compared to other non-amplified method, we showed that this procedure improved the characterization and the quantification of the banding pattern resulting from telomerase extension by reducing the radioactive background. Using this method, we observed that telomerase activity varies markedly in a panel of 39 human cancer cell lines. For example, MCF7 breast cancer cells in culture showed intermediate telomerase activity corresponding to 33.8 ± 3.4% of that of the HeLa cells (reference cell line). Similarly, the telomere length varied with each cell line (average: 6.24 ± 6.16). No correlation between the level of telomerase and telomere length was observed, suggesting that a high processivity is not required to maintain telomeres and that, in some cell lines, another mechanism of telomere elongation can maintain telomere length. From this study, we selected MCF7 and MX1 models that showed reproducible telomerase activity and a relatively limited telomere length for the testing of potential telomere–telomerase interacting agents. Using cisplatin and a new porphyrin-derived compound TMPyP4, we showed that our model was able to detect a down-regulation of the telomerase activity in MCF7 cells in culture and in a human MX1 tumour xenografts. Based on these results, a breast cancer model for evaluating telomerase and telomere interactive agents is proposed.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allsopp, R. C. & Harley, C. B. (1995). Evidence for a critical telomere length in senescent human fibroblasts. Exp Cell Res 219: 130–136.
Bednarek, A. K., Sahin, A., Brenner, A. J., Johnston, D. A. & Aldaz, C. M. (1997). Analysis of telomerase activity in breast cancer: positive detection at the in situ breast carcinoma stage. Clin C Res 3: 11–16.
Blackburn, E. H. (1991). Structure and function of telomeres. Nature 350: 569–573.
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S. & Reddel, R. R. (1995). Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14: 4240–4248.
Burger, A. M., Double, J. A. & Newell, D. R. (1997). Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33: 638–644.
Chadeneau, C., Siegel, P., Harley, C. B., Muller, W. J. & Bacchetti, S. (1995). Telomerase activity in normal and malignant murine tissues. Oncogene 11: 893–898.
Faraoni, I., Turriziani, M., Masci, G., De Vecchis, L., Shay, J. W., Bonmassar, E. & Graziani, G. (1997). Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3: 579–585.
Fisher, B. (1996). Personal contributions to progress in breast cancer research and treatment. Sem Oncol 23: 414–427.
Gilley, D. & Blackburn, E. H. (1994). Lack of telomere shortening during senescence in Paramecium. Proc Natl Acad Sci USA 91: 1955–1958.
Greider, C. W. (1993). Telomerase and telomere-length regulation: lessons from small eukaryotes to mammals. Cold Spring Harbor Symposia on Quantitative Biology 58: 719–723.
Greider, C. W. (1994). Mammalian telomere dynamics: healing, fragmentation shortening and stabilization. Curr Opin Genet & Development 4: 203–211.
Harley, C. B., Kim, N. W., Prowse, K. R., Weinrich, S. L., Hirsch, K. S., West, M. D., Bacchetti, S., Hirte, H. W., Counter, C. M. & Greider, C. W. et al (1994). Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 59: 307–315.
Harley, C. B., Vaziri, H., Counter, C. M. & Allsopp, R. C. (1992). The telomere hypothesis of cellular aging. Exp Gerontol 27: 375–382.
Harley, C. B. & Villeponteau, B. (1995). Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 5: 249–255.
Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., EST program, A., Bass, M. B., Arruda, I. & Robinson, M. O. (1997). A mammalian telomerase-associated protein. Science 275: 973–977.
Healy, K. C. (1995). Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Oncol Res 7: 121–130.
Hiyama, E., Gollahon, L., Kataoka, T., Kuroi, K., Yokoyama, T., Gazdar, A. F., Hiyama, K., Piatyszek, M. A. & Shay, J. W. (1996). Telomerase activity in human breast tumors. J Natl Cancer Inst 88: 116–122.
Holt, S. E., Norton, J. C., Wright, W. E. & Shay, J. W. (1996). Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit. Methods Cell Sci 18: 237–248.
Ishibashi, T. & Lippard, S. J. (1998). Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 95: 4219–4223.
Izbicka, E., Wheelhouse, R. T., Raymond, E., Davidson, K. K., Lawrence, R. A., Sun, D., Windle, B. E., Hurley, L. H. & Won Hoff, D. D. (1999). Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 59: 639–644.
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L. & Shay, J. W. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015.
Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W. & Harley, C. B. (1992). Telomere end-replication problem and cell aging. J Mol Biol 225: 951–960.
Marcand, S., Gilson, E. & Shore, D. (1997). A protein-counting mechanism for telomere length regulation in yeast. Science 275: 986–990.
Piccart, M., Raymond, E., Aapro, M., Eisenhauer, E. A. & Cvitkovic, E. (1995). Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer 31A: 1–10.
Plowman, J., Dykes, D. J., Hollingshead, M., Simpson-Herren, L. & Alley, M. C. (1997). Human tumor xenograft models in NCI drug development. In Anticancer Drug Development Guide, Teicher BA Humana Press: Totowa, NJ 101–125.
Price, C. M. (1993). Telomere structure and function. Ind J Biochem Biophys 30: 77–82.
Prowse, K. R. & Greider, C. W. (1995). Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 92: 4818–4822.
Prowse, K. R., Avilion, A. A. & Greider, C. W. (1993). Identification of a non-processive telomerase activity from mouse cells. Proc Natl Acad Sci USA 90: 1493–1497.
Raymond, E., Sun, D., Chen, S-F, Windle, B. & Von Hoff, D. D. (1996). Agents that target telomerase and telomeres. Curr Opin Biotechnol 7: 583–591.
Sharma, S., Raymond, E., Soda, H., Sun, D., Hilsenbeck, S. G., Sharma, A., Izbicka, E., Windle, B. & Von Hoff, D. D. (1997). Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 8: 1063–1074.
Shay, J. W., Van Der Haegen, B. A., Ying, Y. & Wright, W. E. (1993a). The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 209: 45–52.
Shay, J. W., Wright, W. E. & Werbin, H. (1993b). Toward a molecular understanding of human breast cancer: a hypothesis. Breast Cancer Res Treat 25: 83–94.
Shay, J. W., Brasiskyte, D., Ouellette, M., Piatyszek, M. A., Werbin, H., Ying, Y. & Wright, W. E. (1994). Analysis of telomerase and telomeres. In Methods in Molecular Genetics Part C, Genes and Chromosome Analysis 5: Adolph KW Academic Press: New York 263–280.
Shay, J. W., Piatyszek, M. A., Word, R. A., Gazdar, A. F., Wright, W. E., Kim, N. W., Weinrich, S. L., Prowse, K. R., Harley, C. B., Hiyama, E., Hiyama, K., Mehle, C., Roos, G., Sommerfeld, H. J., Meeker, A. K. & Coffey, D. S. (1995a). You have not heard the end of it: telomeres, time, telomerase and tumors (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res 36: 673
Shay, J. W., Tomlinson, G., Pityszek, M. A. & Gollahon, L. S. (1995b). Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li–Fraumeni syndrome. Mol Cell Biol 15: 42–432.
Sun, D., Chen, S-F & Von Hoff, D. (1996). A sensitive and rapid assay method of human telomerase using dynabeads. In 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Lobbezoo MW 71 (A240) Kluwer: Amsterdam
Sun, D., Thompson, B., Cathers, B. E., Salazar, M., Kerwin, S. M., Trent, J. O., Jenkins, T. L., Neidle, S. & Hurley, L. H. (1997). Inhibition of human telomerase by G-Quadruplex-interactive compounds. J Med Chem 40: 2113–2116.
Thompson, B., Salazar, M., Sun, D., Jenkins, T., Neidle, S. & Hurley, L. (1996). Telomerase inhibition by G-quartet interactive compounds. In 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Lobbezoo MW 71 (A243) Kluwer: Amsterdam
Tsao, J-I, Zhao, Y., Lukas, J., Yang, X., Shah, A., Press, M. & Shibata, D. (1997). Telomerase activity in normal and neoplastic breast. Clin Cancer Res 3: 627–631.
Vojta, P. J. & Barret, J. C. (1995). Genetic analysis of cellular senescence. Biochem Biophys Acta 1242: 29–41.
Wheelhouse, R. T., Sun, D., Han, H., Han, F. X. & Hurley, L. H. (1998). Cationic porphyrins as telomerase inhibitors: the interaction of tetra (N-methyl-4-pyridyl) porphyrine with quadruplex DNA. J Am Chem Soc 120: 3261–3262.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Raymond, E., Sun, D., Izbicka, E. et al. A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay. Br J Cancer 80, 1332–1341 (1999). https://doi.org/10.1038/sj.bjc.6690526
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690526
Keywords
This article is cited by
-
THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Clinical Epigenetics (2022)
-
DNA adducts of antitumor cisplatin preclude telomeric sequences from forming G quadruplexes
JBIC Journal of Biological Inorganic Chemistry (2009)